The Food and Drug Administration will review three potential blockbuster drugs in early September. Observers say the agency may raise the bar after the high profile drug safety stories of the last year. The three new drugs include Pfizer's inhaled insulin Exubera and two drugs developed by Bristol-Myers Squibb: the new rheumatoid arthritis treatment Orencia, and Pargluva, which targets adult-onset diabetes.

- see this story [1] in The Wall Street Journal (sub. req.)